Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$12.00
+0.8%
$10.74
$7.80
$28.09
$654.72MN/A583,828 shs289,451 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.57
+0.1%
$13.11
$7.66
$27.38
$170.82M0.39191,866 shs74,897 shs
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$8.61
-0.2%
$7.51
$4.95
$9.62
$616.56M0.95478,649 shs455,147 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.51
+10.2%
$5.08
$4.16
$14.45
$765.45M1.281.60 million shs2.66 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-0.34%-1.16%+13.01%+6.63%+1,189,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+3.44%+4.80%+7.71%+6.69%+70.23%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
+2.86%+1.65%+33.59%+40.33%-4.43%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+1.21%+12.61%-0.60%-5.30%-39.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3686 of 5 stars
3.51.01.72.73.42.51.3
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
2.3535 of 5 stars
0.01.00.00.04.10.83.1
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
3.2127 of 5 stars
3.51.00.00.03.33.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$32.25168.76% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50124.76% Upside
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
0.00
N/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.90
Moderate Buy$26.80386.39% Upside

Current Analyst Ratings Breakdown

Latest LFVN, SIGA, BCAX, and VIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
8/27/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$12.00 ➝ $14.00
8/22/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$41.00 ➝ $40.00
8/18/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$36.00
8/12/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy$12.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$222.35M0.77$0.91 per share14.85$2.05 per share6.62
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$138.72M4.44$0.86 per share10.03$2.92 per share2.95
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$74.21M10.31N/AN/A$6.82 per share0.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6919.67N/A4.12%34.67%15.24%9/4/2025 (Estimated)
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
$59.21M$1.137.626.89N/A45.73%40.52%35.62%11/6/2025 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)

Latest LFVN, SIGA, BCAX, and VIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54-$0.50+$0.04-$0.50N/AN/A
8/6/2025Q2 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 million
8/5/2025Q2 2025
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A$0.49N/A$0.49N/A$81.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.33%N/A26.09%3 Years
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A

Latest LFVN, SIGA, BCAX, and VIR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/28/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.37%9/8/20259/8/20259/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
25.80
25.80
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
N/A
10.09
8.52
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
7.01
7.01

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
55.40%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
1.95%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.56 millionN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Siga Technologies Inc. stock logo
SIGA
Siga Technologies
4071.61 million70.21 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.92 million116.69 millionOptionable

Recent News About These Companies

Bank of America Upgrades Vir Biotechnology (NASDAQ:VIR) to Buy
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up After Analyst Upgrade
Vir Stock Soars After BofA Boosts Rating on Liver Therapy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$12.00 +0.10 (+0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$11.70 -0.30 (-2.46%)
As of 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.57 +0.02 (+0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$13.80 +0.23 (+1.69%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Siga Technologies stock logo

Siga Technologies NASDAQ:SIGA

$8.61 -0.02 (-0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$8.49 -0.12 (-1.39%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.51 +0.51 (+10.20%)
Closing price 04:00 PM Eastern
Extended Trading
$5.52 +0.00 (+0.09%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.